National Horizon Scanning Centre. Pregabalin (Lyrica) for fibromyalgia. September 2007
|
|
- Jason Willis
- 5 years ago
- Views:
Transcription
1 Pregabalin (Lyrica) for fibromyalgia September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes. The Research Programme is part of the National Institute for Health Research
2 Target group Adults with fibromyalgia. Pregabalin (Lyrica) for fibromyalgia Background Fibromyalgia is a chronic condition characterised by muscle-tendon tenderness, pain in fibromuscular tissue, abdominal pain, fatigue, poor quality sleep, stiffness on waking, depression, temporo-mandibular joint dysfunction, headaches and multiple chemical sensitivity syndrome. The American Rheumatology Society (ARS) 1990 classification criteria state that for the diagnosis of fibromyalgia, the patient must have a history of widespread pain (chronic pain in all four quadrants of the body for at least 3 months) and experience excessive tenderness on at least 11 of 18 identified tender point sites 1. The pain associated with fibromyalgia is generally continuous, but can fluctuate in severity 2. There are currently no diagnostic tests to positively diagnose fibromyalgia. Technology description Pregabalin is an [alpha] 2 -[delta] ligand that has analgesic, anxiolytic and anticonvulsant properties. It is thought that pregabalin binds to voltage-gated calcium channels in the central nervous system, modifying the release of neurotransmitters. It is anticipated that pregabalin will be administered orally at doses of mg per day divided into 2 or 3 doses. Pregabalin is currently licensed for: Epilepsy; Neuropathic pain; and Generalised anxiety disorder. Pregabalin is also in phase III clinical trials for HIV-associated neuropathy. Innovation and/or advantages There are currently no licensed drugs for fibromyalgia, therefore if licensed pregabalin may be one of the first specific drug treatments. Developer Pfizer Ltd. Place of use Home care e.g. home dialysis Secondary care e.g. general, non-specialist hospital General public e.g. over the counter Community or residential care e.g. Specialist nurses in pain clinics Tertiary care e.g. highly specialist services or hospital Other: Primary care e.g. used by GPs or practice nurses Emergency care e.g. paramedic services, trauma care Availability, launch or marketing dates, and licensing plans: Pregabalin is in phase III clinical trials. NHS or Government priority area: This topic is relevant to the Long-term (Neurological) Conditions National Service Framework (NSF) and the Musculoskeletal Services Framework (MSF), 2
3 Relevant guidance No relevant guidance identified. Clinical need and burden of disease Global population surveys estimate the prevalence of fibromyalgia between 0.7%-4.5% (equivalent to 273,000 to 1.76 million adults in England and Wales) 3. The incidence of fibromyalgia in primary care in the UK is estimated at 0.035% (14,700 people newly diagnosed each year) 4. The majority of people affected by fibromyalgia are women. In most cases, fibromyalgia develops between the ages of 30 and 60 years, but it can develop in people of any age, including children and the elderly 5. The cause of fibromyalgia is unknown, but may relate to serotonin and norepinephrine system dysfunction. Existing comparators and treatments Non-pharmaceutical management options for fibromyalgia include: exercise programmes, cognitive behavioural therapy (CBT), relaxation, acupuncture and patient support. Classes of drugs used off-label to manage fibromyalgia include: Anticonvulsants such as gabapentin or carbamazepine, to treat muscle spasms, anxiety and reduce pain; Low-dose tricyclic antidepressants such as amitryptyline, to reduce pain and aid sleep 6 ; Selective serotonin re-uptake inhibitors (SSRIs) such as fluoxetine; Analgesics and anti-inflammatory drugs such as paracetamol, non-steroidal antiinflammatory drugs (NSAIDs) and narcotic analgesics, to reduce pain; Local anaesthetic mixed with corticosteroids may also be injected into areas providing temporary pain relief. Efficacy and safety Trial name Sponsor Pfizer Pfizer Status Abstract Abstract Location USA USA Design Randomised, double-blind, placebo- Randomised, double-blind, placebotrial. controlled, monotherapy trial. controlled Participants in N=750, > 18 years, 95% female, mean N=1051, >18 years, 93% female, trial age=50 yrs, median fibromyalgia 88% white, mean age=50 yrs, FMS syndrome (FMS) duration=10 yrs, duration=7.8 yrs, mean Visual baseline mean pain score=6.7. Patients Analogue Scale (VAS) pain score= 78 met American College of mm. Patients meet ACR criteria. Rheumatology (ACR) criteria. Randomised to placebo or pregabalin 300, 450 or 600 mg per day. Follow-up 14 weeks. 26 weeks. Outcomes Symptoms, pain, Patient Global Loss of therapeutic response (LTR): Improvement of Change (PGIC) & <30% reduction in VAS pain score. Key results safety Differences from placebo in mean change from baseline to endpoint in pain score for: 300, 450 and 600 mg were: 0.71, 0.98 and 1.00 respectively. PGIC for 300, 450 and 600 mg was: 68%, 78% and 66% respectively Pregabalin significantly delayed time to LTR: 25% LTR by day 7 for placebo, compared to day 34 for pregabalin. 174 (61%) of patients on placebo lost therapeutic response compared to 90 (32%) on pregabalin. 3
4 Major adverse effects compared to 48% placebo. Dizziness (35.8%) and somnolence (18.0%). Pregabalin was more effective than placebo for relieving pain and improving global assessment, functional status, sleep and fatigue. Dizziness, somnolence, sinusitis, arthralgia and anxiety. Trial name A Phase III extension. A Phase III. Sponsor Pfizer Pfizer Status Unp ublished, completed. Unpublished, completed. Location USA USA Design Non-randomised, open-label, Non-randomised, open-label, uncontrolled. uncontrolled. Participants in N=428, >18 years. Patients who N=500, >18 years. Patients met ACR trial participated in A (a non- criteria. randomised, open-label, uncontrolled trial). Follow-up 1-year open-label extension. 12 weeks. Primary outcome Long-term safety and tolerability. Safety. Expected reporting date Recruitment began in January 2005 with study completion in June Results not reported. Recruitment began in Feb Results not reported. Trial name A Phase III. A Phase III extension. Sponsor Pfizer Pfizer Status Ongoing Ongoing Location International International Design Randomised, double-blind, placebo controlled. Non-randomised, open-label, uncontrolled. Participants in N=740, >18. Patients meet ACR N=740, >18. Patients participated in trial criteria and score 40 mm on pain A (VAS). Follow-up 14 weeks. 12 weeks. Primary outcome Daily pain. Long-term safety and tolerability. Secondary Global evaluation, sleep, fatigue, - outcomes health-related quality of life, functioning, pain, mood disturbance. Expected reporting date Study began June Study began Dec E stimated cost and cost impact The cost per treatment period and relevant comparators is: Daily dose range Annual cost a Pregabalin mg Gabapentin mg Carbamazepine mg Amitriptyline mg a BNF No. 53. March
5 Potential or intended impact speculative Patients Reduced morbidity Reduced mortality or increased Improved quality of life for survival patients and/or carers Quicker, earlier or more accurate Other: Non identified diagnosis or identification of disease Services Increased use Service reorganisation required Staff or training required Decreased use Other: Non identified C osts Increased unit cost compared to Increased costs: more patients Increased costs: capital alternative coming for treatment investment needed New costs: Savings: Other: References 1 Wolfe F, Smythe HA, Yunus MB et al. The American College of Rheumatology 1990 Criteria for the classification of fibromyalgia: Report of the multicenter criteria committee. Arthritis & Rheumatism. 1990; 33 (2): Turk DC, Robinson JP, Burwinkle T. Prevalence of fear of pain and activity in patients with fibromyalgia syndrome. The Journal of Pain. 2004; 5 (9): White KP & Harth M. Classification, epidemiology and natural history of fibromyalgia. Current Pain & Headache Reports. 2001; 5: Gallagher AM, Thomas JM. Hamilton WT et al. Incidence of fatigue symptoms and diagnoses presenting in UK primary care from 1990 to Journal of the Royal Society of Medicine 2004; 97: NHS Direct online: Accessed July Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. Journal of the American Medical Association. 2004;292 (19): Arnold LM, Russell IJ, Duan WR et al. Pregabalin for management of fibromyalgia syndrome (FMS): a 14- week, randomised, double-blind, placebo-controlled, monotherapy trial. Presented at the 59 th Annual Scientific Meeting of the American Academy of Neurology, April 28 May 5, 2007, Boston 8 Crofford LJ, Simpson SL, Young JP et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief: (FREEDOM) trial: a six-month, double-blind, placebo-controlled trial of treatment with pregabalin. Presented at the 26 th Annual Scientific Meeting of the American Pain Society, May 2-5, 2007, Washington DC 9 ClinicalTrials.gov. A long-term, open-label, safety trial of pregabalin in patients with fibromyalgia. Available at: [Accessed: 04/07/07]. 10 ClinicalTrials.gov. A 12-week, open-label, safety trial of pregabalin in patients with fibromyalgia. Available at: [Accessed: 04/07/07]. 11 ClinicalTrials.gov. A 14-week, randomised, double-blind, placebo-controlled trial of pregabalin twice daily in patients with fibromyalgia. Available at: [Accessed: 04/07/07]. 12 ClinicalTrials.gov. A 12-week, open-label, safety trial of pregabalin in patients with fibromyalgia. Available at: [Accessed: 04/07/07]. 5
6 The National Institute for Health Research Research Programme is funded by the Department of Health. The views expressed in this publication are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health The, Department of Public Health and Epidemiology University of Birmingham, Edgbaston, Birmingham, B15 2TT, England Tel: +44 (0) Fax +44 (0)
National Horizon Scanning Centre. Ampligen for chronic fatigue syndrome. December 2007
Ampligen for chronic fatigue syndrome December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationNational Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007
Rituximab (MabThera) for chronic lymphocytic leukaemia This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer. December 2007
Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationThe Role of Pregabalin in Fibromyalgia
The Role of Pregabalin in Fibromyalgia Sofia Exarchou Resident at Internal Medicine and Rheumatology at the University Hospital of Skåne, Malmö-Lund Metsovo Greece 2011 History Gowers 1904 Hench 1976 Smythe
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationNational Horizon Scanning Centre. Azacitidine (Vidaza) for myelodysplastic syndrome. September 2007
Azacitidine (Vidaza) for myelodysplastic syndrome September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationHorizon Scanning Technology Briefing. Alvimopan (Entrareg ) for opioid-induced bowel disfunction. National Horizon Scanning Centre.
Horizon Scanning Technology Briefing National Horizon Scanning Centre Alvimopan (Entrareg ) for opioid-induced bowel disfunction August 2006 This technology briefing is based on information available at
More informationHorizon Scanning Technology Summary. Methylnaltrexone for opioid induced constipation in advanced illness and palliative care
Horizon Scanning Technology Summary National Horizon Scanning Centre Methylnaltrexone for opioid induced constipation in advanced illness and palliative care April 2007 This technology summary is based
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationNational Horizon Scanning Centre. Dronedarone (Multaq) for atrial fibrillation and atrial flutter. December 2007
Dronedarone (Multaq) for atrial fibrillation and atrial flutter December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationHorizon Scanning Technology Briefing. Cetuximab (Erbitux) for metastatic colorectal cancer. National Horizon Scanning Centre.
Horizon Scanning Technology Briefing National Horizon Scanning Centre Cetuximab (Erbitux) for metastatic colorectal cancer December 2006 This technology summary is based on information available at the
More informationRilonacept for cryopyrin associated periodic syndromes
Rilonacept for cryopyrin associated periodic syndromes August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationNational Horizon Scanning Centre. Methylnaltrexone (MOA-728) for postoperative ileus. April 2008
(MOA-728) for postoperative ileus April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationHorizon Scanning Technology Summary. Cyanocobalamin nasal spray (Nascobal) for vitamin B12 deficiency. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Cyanocobalamin nasal spray (Nascobal) for vitamin B12 deficiency April 2007 This technology summary is based on information available
More informationHorizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research
More informationNational Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008
Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationNational Horizon Scanning Centre. GV1001 for advanced and/or metastatic pancreatic cancer. April 2008
GV1001 for advanced and/or metastatic pancreatic cancer April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationNational Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008
Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory January 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationScottish Medicines Consortium
Scottish Medicines Consortium pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica ) No. (389/07) Pfizer Limited 6 July 2007 The Scottish Medicines Consortium has completed
More informationNational Horizon Scanning Centre. Decitabine (Dacogen) for myelodysplastic syndrome. April 2008
Decitabine (Dacogen) for myelodysplastic syndrome April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationNational Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008
Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationEribulin for locally advanced or metastatic breast cancer third line; monotherapy
Eribulin for locally advanced or metastatic breast cancer third line; monotherapy April 2009 This technology summary is based on information available at the time of research and a limited literature search.
More informationNational Horizon Scanning Centre. Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids.
Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids May 2008 This technology summary is based on information available at the time of research and a limited
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationCabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel
Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a
More informationHorizon Scanning Technology Summary. Temozolomide (Temodal) for advanced metastatic melanoma. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Temozolomide (Temodal) for advanced metastatic melanoma April 2007 This technology summary is based on information available at the
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationFibromyalgia (FM) is a common, chronic pain disorder
ORIGINAL ARTICLE Long-term Maintenance of Response Across Multiple Fibromyalgia Symptom Domains in a Randomized Withdrawal Study of Pregabalin Lynne Pauer, MS,* Gary Atkinson, MSc,w T. Kevin Murphy, PhD,z
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationHorizon Scanning Technology Briefing. Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer
Horizon Scanning Technology Briefing National Horizon Scanning Centre Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer December 2006 This technology summary is based on
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationEverolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery
Everolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery April 2011 This technology summary is based on information
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationFibromyalgia: Current Trends and Concepts
Fibromyalgia: Current Trends and Concepts Dr. Brian Kahan Fellow American Academy of Physical Medicine and Rehabilitation Diplomat American Academy of Pain Medicine American College of Rheumatology (ACR)
More informationNational Horizon Scanning Centre. Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours. August 2008
Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours August 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationFibromyalgia Update. Presenter: Manfred Harth MD FRCPC
Fibromyalgia Update Presenter: Manfred Harth MD FRCPC Fibromyalgia Update Manfred Harth MD FRCPC Disclosures Member Pfizer Canada Medical Advisory Committee on Lyrica (till April 2013) Abbvie : Payment
More informationOlesoxime for amyotrophic lateral sclerosis first line
Olesoxime for amyotrophic lateral sclerosis first line May 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationHorizon Scanning Technology Briefing National Helical Tomotherapy Horizon Hi-ART System for Scanning external cancer Centre radiotherapy August 2006
Horizon Scanning Technology Briefing National Horizon Scanning Centre Helical Tomotherapy Hi-ART System for external cancer radiotherapy August 2006 This technology briefing is based on information available
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationAfamelanotide for erythropoietic protoporphyria and congenital erythropoietic porphyria
Afamelanotide for erythropoietic protoporphyria and congenital erythropoietic porphyria This technology summary is based on information available at the time of research and a limited literature search.
More informationFibromyalgia: What Primary Care Providers Need to Know
Learning Objectives Fibromyalgia: What Primary Care Providers Need to Know Susan Hutchinson, MD Director, Orange County Migraine & Headache Center Volunteer Clinical Faculty, UC Irvine Department of Family
More informationNational Horizon Scanning Centre. Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment
Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment April 2008 This technology summary is based on information available at the time of research and
More informationRiociguat for chronic thromboembolic pulmonary hypertension
Riociguat for chronic thromboembolic pulmonary hypertension This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationThe Effect of Anxiety and Depression on Improvements in Pain in a Randomized, Controlled Trial of Pregabalin for Treatment of Fibromyalgia
Blackwell Publishing IncMalden, USAPMEPain Medicine1526-2375American Academy of Pain Medicine? 200788633638 RESEARCH ARTICLEAnxiety and Depression in Fibromyalgia PatientsArnold et al. PAIN MEDICINE Volume
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More information10/26/2013. Mary-Ann Fitzcharles is a consultant, speaker, or member of an advisory board for the following companies: Lilly, Purdue, Pfizer, Valeant
Mary-Ann Fitzcharles, MBChB Associate Professor of Medicine Division of Rheumatology and Alan and Louise Edwards Pain Management Center McGill University, Montreal Canada Mary-Ann Fitzcharles is a consultant,
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationRecommendations for the Management of Fibromyalgia
2011 UBM Medica. Reprinted with permission from Medical Progress 2011 Vol. 38 No. 1. Pain management Recommendations for the Management of Fibromyalgia The Multidisciplinary Panel on Neuropathic Pain Chen
More informationAdvice following an Independent Review Panel (IRP)
Scottish Medicines Consortium Advice following an Independent Review Panel (IRP) Pregabalin 25, 50, 75, 100, 150, 200 and 300mg capsules (Lyrica ) Pfizer No. 157/05 7 July 2006 The Scottish Medicines Consortium
More informationHorizon Scanning Technology Summary. Magnetic resonance angiography (MRA) imaging for the detection of coronary artery disease
Horizon Scanning Technology Summary National Horizon Scanning Centre Magnetic resonance angiography (MRA) imaging for the detection of coronary artery disease April 2007 This technology summary is based
More informationScottish Medicines Consortium
Scottish Medicines Consortium duloxetine 30mg and 60mg capsules (Cymbalta ) No. (285/06) Eli Lilly and Company Limited/Boehringer Ingelheim 4 August 2006 The Scottish Medicines Consortium has completed
More informationFibromyalgia or Arthritis
Fibromyalgia or Arthritis Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationFibromyalgia or Arthritis
Fibromyalgia or Arthritis All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical, including photocopying,
More informationFIBROMYALGIA. Raj Saini Greenbrook Pharmacy
FIBROMYALGIA Raj Saini Greenbrook Pharmacy www.greenrx.ca 519-742-9955 OBJECTIVES Introduction Causes/Symptoms/Diagnosis Stress, Hormonal Balance & Fibromyalgia Treatment-Pharmaceutical Treatment-Natural
More informationHorizon Scanning Technology Briefing. Magnetic resonance spectroscopy for prostate cancer. National Horizon Scanning Centre.
Horizon Scanning Technology Briefing National Horizon Scanning Centre Magnetic resonance spectroscopy for prostate cancer August 2006 This technology briefing is based on information available at the time
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationAssistant Professor. Dr.Khudair Al-bedri Consultant Rheumatology & Internal Medicine.
Assistant Professor Dr.Khudair Al-bedri Consultant Rheumatology & Internal Medicine. Fibromyalgia Fibromyalgia is a syndrome of chronic pain and the presence of hyperalgesic points at specific anatomical
More information5.9. Rehabilitation to Improve Central Pain
5.9. Rehabilitation to Improve Central Pain Evidence Tables and References Canadian Best Practice Recommendations for Stroke Care 2011-2013 Update Last Updated: June 25 th, 2013 Contents Search Strategy...
More informationVolume 9; Number 3 March 2015 PRESCRIBING AND DISPENSING PREGABALIN FOR NEUROPATHIC PAIN
Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationComparative Efficacy of Pharmacological and Nonpharmacological Interventions in Managing Primary and Secondary Outcomes of Fibromyalgia Syndrome
Literature Review Comparative Efficacy of Pharmacological and Nonpharmacological Interventions in Managing Primary and Secondary Outcomes of Fibromyalgia Syndrome * Medical University of the Americas,
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationFibromyalgia: What a Pain!
Fibromyalgia: What a Pain! WWW.RN.ORG Reviewed May, 2017, Expires May, 2019 Provider Information and Specifics available on our Website Unauthorized Distribution Prohibited 2017 RN.ORG, S.A., RN.ORG, LLC
More informationIs Sodium Oxybate a Safe and Effective Treatment for Patients with Fibromyalgia
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Is Sodium Oxybate a Safe and Effective
More informationNational Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationGateshead Pain Guidelines for Chronic Conditions
Gateshead Pain Guidelines for Chronic Conditions Effective Date: 13.2.2013 Review Date: 13.2.2015 Gateshead Pain Guidelines: Contents PAIN GUIDELINES Chronic Non-Malignant Pain 5 Musculoskeletal Pain 6
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationTRANSPARENCY COMMITTEE OPINION. 9 May 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2007 LYRICA 25 mg capsules Pack of 56 capsules (CIP: 365 127-0) Pack of 84 capsules (CIP: 365 135-3) Pack of
More informationMaking sense of fibromyalgia syndrome. Charles Radis D.O. Clinical Professor of Medicine UNECOM
Making sense of fibromyalgia syndrome Charles Radis D.O. Clinical Professor of Medicine UNECOM Goals 1. How do we diagnose fibromyalgia syndrome in patients presenting with widespread pain? 2. Discuss
More informationBotulinum toxin A (Dysport) for hyperhidrosis of the axillae
April 2016 Horizon Scanning Research & Intelligence Centre Botulinum toxin A (Dysport) for hyperhidrosis of the axillae LAY SUMMARY This briefing is based on information available at the time of research
More informationAnalgesia in patients with impaired renal function Formulary Guidance
Analgesia in patients with impaired renal function Formulary Guidance Approved by Trust D&TC: January 2010 Revised March 2017 Contents Paragraph Page 1 Aim 4 2 Introduction 4 3 Assessment of renal function
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationFibromyalgia summary. Patient leaflets from the BMJ Group. What is fibromyalgia? What are the symptoms?
Patient leaflets from the BMJ Group Fibromyalgia summary We all get aches and pains from time to time. But if you have long-term widespread pain across your whole body, you may have a condition called
More informationCOMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Osteoarthritis Pain
More informationHorizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available
More informationNurse Practitioners Education, Awareness, and Therapeutic Approaches for the Management of Fibromyalgia
RESEARCH 2.0 ANCC Contact Hours Nurse Practitioners Education, Awareness, and Therapeutic Approaches for the Management of Fibromyalgia Linda Hughes Jean Adair Feng Feng Stephanie Maciejewski Harsha Sharma
More informationA Patient s Guide to Fibromyalgia
A Patient s Guide to Fibromyalgia 651 Old Country Road Plainview, NY 11803 Phone: 5166818822 Fax: 5166813332 p.lettieri@aol.com DISCLAIMER: The information in this booklet is compiled from a variety of
More information10/19/12. Moving from Mechanisms to Treatment in Chronic Pain Patients. Daniel Clauw, MD Disclosures
10/19/12 Moving from Mechanisms to Treatment in Chronic Pain Patients Daniel Clauw, MD University of Michigan Ann Arbor, MI Daniel Clauw, MD Disclosures Research/Grants: Forest Laboratories, Inc.; Nuvo
More informationSUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)
9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS
More information